Task X21: Preparedness for Testing NIAID Priority Vaccines in General Safety and Toxicology Studies

任务 X21：在一般安全性和毒理学研究中测试 NIAID 优先疫苗的准备

• 批准号: 10356788
• 负责人: RANDI HORNBACK
• 金额: $ 42.65万
• 依托单位: BATTELLE CENTERS/PUB HLTH RES & EVALUATN
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-07-01 至 2022-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10356788
• 关键词: 2019-nCoV; Biological; Bioterrorism; COVID-19; Clinical; Communicable Diseases; Contracts; Development; Emerging Communicable Diseases; Feasibility Studies; National Institute of Allergy and Infectious Disease; Phase; Readiness; Safety; Sampling; Services; Testing; Toxicity Tests; Toxicology; Vaccines; assay development; efficacy testing; evaluation/testing; immunogenicity; novel coronavirus; novel vaccines; product development; safety testing; testing services; therapeutic development

The Evaluation and Testing Services (ETS) for Vaccines and Other Biologics for Infectious Diseases contract provides a variety of product development services from early feasibility studies through manufacture of Phase I/II material, including assay development; immunogenicity and efficacy testing; clinical and nonclinical sample testing; and safety and toxicity testing. These services will facilitate the development and introduction of new vaccines and biologics against potential agents of bioterrorism and emerging and re-emerging infectious diseases.

传染病疫苗和其他生物制剂的评估和测试服务（ETS）合同提供了从早期可行性研究到I/II期材料生产的各种产品开发服务，包括检测开发;免疫原性和有效性测试;临床和非临床样品测试;以及安全性和毒性测试。 这些服务将促进开发和引进新的疫苗和生物制剂，以对付潜在的生物恐怖主义制剂以及新出现和重新出现的传染病。